On July 26, 2023, Nexo Therapeutics (Nexo), a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies, emerged from stealth with $60 million Series A financing led by founding investor Versant Ventures with participation from New Enterprise Associates and Cormorant Asset Management. Wilson Sonsini Goodrich & Rosati advised Versant Ventures and New Enterprise Associates on the deal.

The financing supports Nexo’s platform that combines the power of covalent ligand discovery and chemical biology to unlock a pipeline of novel cancer therapies directed against previously intractable targets.

The Wilson Sonsini team that advised Versant Ventures and New Enterprise Associates included Dan Koeppen, Meghan Burton, and Karl Kobylecki.

For more information, please see Nexo’s news release. Additional coverage can be found on Pharmaceutical Technology and Chemistry and Engineering News.